CheckMate 577: adjuvant nivolumab in resected oesophageal or gastro-oesophageal junction cancer
A year of nivolumab after chemoradiotherapy and surgery doubled disease-free survival in patients with oesophageal or junctional cancer who still had residual tumour at surgery, the first adjuvant therapy to work in this setting.
Overview
Phase 3 placebo-controlled trial of 794 patients with resected stage II to III oesophageal or gastro-oesophageal junction cancer (both histologies) and residual pathological disease after neoadjuvant chemoradiotherapy, randomised 2:1 to nivolumab or placebo for up to one year.
Median disease-free survival was 22.4 versus 11.0 months (hazard ratio 0.69), with benefit in both squamous and adenocarcinoma and regardless of PD-L1 expression; grade 3 to 4 treatment-related adverse events were 13 versus 6 percent.
- Median disease-free survival 22.4 vs 11.0 months; hazard ratio 0.69.
- Benefit in squamous (hazard ratio 0.61) and adenocarcinoma (0.75).
Adjuvant nivolumab is standard for patients with residual disease after trimodality therapy for oesophageal cancer.
- Overall survival data pending.
- Applies only after neoadjuvant chemoradiotherapy, not after perioperative chemotherapy.
Similar pages
not linked directly; found by shared links- Key paperCheckMate 648: nivolumab combination therapy in advanced oesophageal squamous cell carcinoma
Shares Oesophageal squamous cell carcinoma, New England Journal of Medicine, Nivolumab.
- Key paperCROSS: preoperative chemoradiotherapy for oesophageal or junctional cancer
Shares Oesophageal squamous cell carcinoma, New England Journal of Medicine.
- TrialA Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- PersonRonan J. Kelly
Shares CheckMate 577, Nivolumab.
- PairingCROSS chemoradiation → surgery → adjuvant nivolumab if residual disease
Shares CheckMate 577, Nivolumab.
- Key paperCheckMate 238: adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
Shares New England Journal of Medicine, Nivolumab.
- Key paperCheckMate 141: nivolumab for recurrent head and neck squamous cell carcinoma after platinum
Shares New England Journal of Medicine, Nivolumab.
- Key paperCheckMate 214: nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma
Shares New England Journal of Medicine, Nivolumab.